Key facts
- ADvantage Therapeutics’s last known valuation is $81.0M (Jul 2025).
- It has raised $18.7M across 3 recorded rounds; the latest was Early Stage VC ($13.7M) in Jun 2023.
- Notable investors include quadraScope Ventures.
- ADvantage Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently Jul 2025 ($13.7M sold to 24 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ADvantage Therapeutics
Funding rounds
3 roundsAbout ADvantage Therapeutics
Operator of a pharmaceutical company intended to develop therapeutics for patients suffering from neurodegenerative disease. The company specializes in developing therapies to treat Alzheimer's Disease (AD) and potentially paradigm-changing therapies, enabling healthcare professionals to better treat neurodegenerative conditions.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2021
- Employees
- 12
- Website
- advantagetherapeutics.com/
- Ownership
- Privately Held (backing)
ADvantage Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ADvantage Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ADvantage Therapeutics in its N-PORT filings yet. We sweep new filings monthly.